Market revenue in 2022 | USD 68.7 million |
Market revenue in 2030 | USD 159.0 million |
Growth rate | 11.1% (CAGR from 2022 to 2030) |
Largest segment | Stem cells |
Fastest growing segment | Other Products |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stem cells, Other Products |
Key market players worldwide | Boehringer Ingelheim, Zoetis Inc Class A, Dechra Pharmaceuticals, Integra Lifesciences Holdings Corp, Ardent Health Services, Vetherapy, VET-STEM INC., Enso Discoveries, Animal Cell Therapies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to veterinary regenerative medicine market will help companies and investors design strategic landscapes.
Stem cells was the largest segment with a revenue share of 52.4% in 2022. Horizon Databook has segmented the North America veterinary regenerative medicine market based on stem cells, other products covering the revenue growth of each sub-segment from 2018 to 2030.
The North America veterinary regenerative medicine market held the largest share of 41.53% of the global market in 2023, primarily due to the high prevalence of canine osteoarthritis and the limitations of existing treatment options. Regenerative medicine, featuring stem cell transplants, stands out as a cutting-edge and FDA-approved approach for addressing orthopedic problems in dogs.
It is a highly promising solution for improving the quality of life for pets suffering from arthritis. The rising prevalence of osteoarthritis in dogs, affecting nearly 40% of the canine population in the U.S., poses a significant health concern. This condition is physically painful and takes a toll on the emotional wellbeing of pets.
Existing treatment options for osteoarthritis in dogs have limitations, including low effectiveness, challenges in administration, and safety concerns, resulting in a low treatment rate. Regenerative Medicine, notably using FDA-approved stem cell transplants, emerges as a groundbreaking solution. It promotes joint regeneration and addresses various canine orthopedic issues, including arthritis, tendon and ligament injuries, cartilage damage, and bone fractures.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America veterinary regenerative medicine market , including forecasts for subscribers. This continent databook contains high-level insights into North America veterinary regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account